Genelux Corporation (GNLX)
| Market Cap | 131.30M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -15.58M |
| Shares Out | 23.62M |
| EPS (ttm) | -0.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,760 |
| Open | 5.71 |
| Previous Close | 5.86 |
| Day's Range | 5.52 - 5.85 |
| 52-Week Range | 5.35 - 7.94 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About GNLX
Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Our most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus (VACV), a stable DNA virus with a large engineering capacity. We expect to be in the process of obtaining Institutional Review Board approvals and negotiating clinical trial agreements to begin enrollment for our Phase 3 regi... [Read more]
Financial Performance
Financial StatementsNews
Genelux IPO prices at bottom of range
Genelux Corp. priced its initial public offering at $6 a share, the low end of its $6 to $7 a share range, for its stock market debut Thursday on the Nasdaq under the symbol GNLX. With 2.5 million sha...
Genelux Corporation Announces Pricing of Initial Public Offering
WESTLAKE VILLAGE, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux” or “the Company”), a clinical-stage immunotherapy company focused on developing a pipeline of next-generation...
Genelux sets IPO terms, as the biotech could be valued at up to $165 millino
Genelux Corp. GNLX, has set terms for its initial public offering, in which the California-based biotechnology company focused on treating difficult-to-treat tumors could be valued at up to $164.99 mi...